Blastoschizomyces capitatus represents an emerging fungal pathogen in acute leukemia patients. The susceptibility to amphotericin B, 5-fluorocytosine, ketoconazole and fluconazole of nine clinical isolates was evaluated. A specific medium (high resolution medium) was used for testing fluconazole. This agent and 5-fluorocytosine were at least four- to eight-fold more active than amphotericin B and ketoconazole against all isolates but one.
In-vitro comparative activity of fluconazole and other antifungal agents against Blastoschizomyces capitatus / M. Venditti, B. Posteraro, G. Morace, P. Martino. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 3:1(1991 Feb), pp. 13-15.
In-vitro comparative activity of fluconazole and other antifungal agents against Blastoschizomyces capitatus
G. Morace;
1991
Abstract
Blastoschizomyces capitatus represents an emerging fungal pathogen in acute leukemia patients. The susceptibility to amphotericin B, 5-fluorocytosine, ketoconazole and fluconazole of nine clinical isolates was evaluated. A specific medium (high resolution medium) was used for testing fluconazole. This agent and 5-fluorocytosine were at least four- to eight-fold more active than amphotericin B and ketoconazole against all isolates but one.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
